Pharmacobezoars are an uncommon complication caused by conglomeration of medications or medication vehicles in the gastrointestinal (GI) tract. The stomach is the most common site for formation of such bezoars. Bulk-forming laxatives, extended release formulations, drugs (eg, nifedipine, verapamil, procainamide, ferrous sulphate, theophylline, and cholestyramine), prior gastric surgery, and Crohn's disease predispose to bezoar formation. 1 Mesalamine tablets usually release salt at pH 7 in the terminal ileum and colon. The pH of the stomach is usually less than 7, so these tablets do not release salt in stomach. Crohn's disease is a stricturing disease of the GI tract, and stricture at the pylorus may impede the movement of gastric contents, thereby promoting the formation of a pharmacobezoar. Only two similar cases were previously reported in the literature for Crohn's disease patients due to mesalamine tablets. 1,2 In our case, the stricture at the pylorus prevented the tablets from passing beyond the stomach, thus forming pharmacobezoars. Endoscopic examination plays an important role in diagnosing pharmacobezoars. 3 On contrast radiography, a gastric bezoar classically presents as a filling defect within the stomach. 
